AngioTarget is a Dutch biotech company focusing
on the development of new diagnostic and therapeutic strategies for cancer.
induced formation of new blood vessels, the process that is called
angiogenesis, is a target for diagnostic tools and therapeutic
strategies. AngioTarget is dedicated to the development of tracers for
diagnostic imaging of cancer. A recently designed PET tracer is
developed for guidance of therapy decisions, monitoring of therapy
success and prediction of therapy response. AngioTarget also develops
anti-cancer strategies based on targeting the tumor blood vessels.
These strategies are directed against a number of highly specific and
proprietary markers of the tumor vasculature.
March 2017 - AngioTarget and VUMC reach a worldwide exclusive license agreement on technology of the Angiogenesis Laboratory.
June 2016 - AngioTarget receives EU H2020 funding. Call H2020-SMEINT-1-2015.
Project 717287-1 (ANGIO-IMAGE).
January 2014 – AngioTarget receives
Proof of Concept grant from the VUMC TTO office for the development of
its first product.
- AngioTarget signs collaboration and license agreement with VUMC.